Patrick Campbell

A review of data presented at ATTD 2022 dissects what features within smartphone applications created to improve diabetes management actually contribute to improved glycemic control.

Data from the ATLAS trial suggests receiving an S-ICD was associated with a 92% lower risk of major lead-related complications compared to receiving a TV-ICD.

Bristol Myers Squibb announced the FDA's approval of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in a press release on April 28.

Tirzepatide met both coprimary endpoints in SURMOUNT-1, with use contributing to reductions in body weight of up to 22.5% during the 72-week trial and more than 60% of those receiving the 15 mg dose achieving body weight reductions of 20% or more.

An analysis of data from more than 35,000 women in the Women's Health Initiative indicates a history of infertility was independently associated with a 16% increase in risk of incident heart failure, with a 27% increase in risk of HFpEF, in postmenopausal women.

A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.

An observational study from Portugal indicates GnRHa therapy as a treatment for central precocious puberty was associated with an increase in body weight that subsided 1 year after treatment cessation.

The latest scientific statement from the American Heart Association is aimed at improving the awareness of NAFLD and its associated cardiovascular risk among clinicians as well as optimizing diagnosis and early treatment strategies for patients with NAFLD.

Using a trio of diet indices, investigators provide insight into the relationship between adherence to plant-based diets and metabolites linked to decreased risk of type 2 diabetes.

Data from an analysis of a SWAN substudy suggests increased exposure to PFAS was linked to an increased risk of incident diabetes during midlife among women.

A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.

Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.

Viet Le, PA-C, provides perspective on an ACC.22 study examining long-term risk of MACE based on alcohol consumption and whether or not the patient had a history of statin use.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Presented at ACC.22, results of METEORIC-HF demonstrate use of omecamtiv mecarbil was not associated with improvements in exercise capacity or perceived functional ability.

Results of the CHAP project demonstrate active treatment of chronic mild hypertension was associated with reductions in risk of adverse pregnancy outcomes and is unlikely to harm the developing child.

Released on the eve of ACC.22, the 2022 heart failure guidelines represent a collaborative effort by the ACC/AHA/HFSA and include major additions, including a new focus on the use of SGLT2 inhibitors and revisions to the ACC/AHA stages of heart failure.

An analysis of data from 2013-2015 provides insight into the impact of Medicaid expansion under the Affordable Care Act on rate of major diabetes-related amputations and suggests a shift in the distribution of uninsured patients may have driven reductions observed in the study.

An analysis of data from patients with diabetes in VA nursing homes suggests 17% were being overtreated for diabetes and 23% were being potentially overtreated.

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.

Released on March 21, the practice advisory from the American Academy of Neurology advocates for a management approach focused on optimization of medical therapies and exercise over stenting for reducing risk of recurrent events and death in patients with symptomatic intracranial atherosclerotic arterial stenosis

An analysis of survey responses from type 1 diabetes caregivers indicates 10.3% of respondents reported job loss, 26.8% reported experiencing financial difficulty, and 71.9% reporting increased stress levels during the pandemic.

Data from a within-trial cost-effectiveness evaluation of data from the Salt Substitute and Stroke Study suggest use of the 75% sodium chloride 25% potassium chloride salt substitute had a 95% probability of being cost-saving and a greater than 99.9% probability of being cost-effective.

Data from the COSMOS trial demonstrate use of a cocoa flavanol supplement in older adults could cut the risk of cardiovascular death by more than 25%.

A systematic review and meta-analysis details the apparent lack of significant difference for glycemic control observed with subcutaneous insulin infusions versus multiple daily injections in patients with type 1 diabetes using real-time continuous glucose monitoring.

Announced on March 16, the decision to stop the phase 3 EMPA-KIDNEY trial is based on the recommendation of the trial's Independent Data Monitoring Committee and Eli Lilly and Company expect to present full results at an upcoming medical conference.

After previous studies found an increase in the diagnosis of central precocious puberty, investigators launched a new study to assess whether decreases in physical activity might be linked to the increased diagnosis rate.

Funded by the ADA and ADCES, the 2022 National Standards for Diabetes Self-Management Education and Support are aimed at and were released in Diabetes Spectrum on March 9.

With the FDA approval announced by Cordis on March 10, the company is hopeful the S.M.A.R.T. RADIANZ Vascular Stent System can help optimize radial access and improve patient outcomes.

Using multiple composite scores to assess dietary quality, investigators use data from 9 NHANES cycles to provide an overview of the declining diet quality among older adults in the US from 2001-2018.